Fetal period
as source of variability 6-6
Field method
definition 2-6
Fluorescence
in situ
hybridization
chromosome analysis 10-2
Folate
circulating forms 8-4
deficiency 8-5
Fraction correctly classified
definition 3-16
Frequency distribution
see
reference frequency distribution
G
G-banding
chromosome analysis 10-1
Genetic abnormalities in cancer
genetic alterations seen in cancer 11-2
cancer diagnosis and classification 11-15
Genetic disease
carrier detection 10-12
prenatal detection 10-14
reproductive risk assessment 10-12
screening 10-10
Genetic disorders of blood cells
protein deficiency 10-9
protein phenotyping 10-10
Genetic disorders of metabolism
congenital adrenal hyperplasia 10-7, 10-11
model of metabolic fluxes 10-7
newborn screening 10-11
substance accumulation in 10-7
Genetic disorders of plasma proteins
factor VIII deficiency 10-13
protein deficiencies 10-8
protein phenotyping 10-9
Glomerular filtration rate
creatinine clearance rate
calculation 6-4
in adulthood and old age 6-4, 6-8
inulin clearance rate 6-3
H
Half-life
definition 12-13
determinants of 7-1
Hair analysis
in the evaluation of nutrition status 8-7
Hemophilia
see
factor VIII deficiency
Hepatitis, viral
markers 9-16
Hereditary nonpolyposis colorectal cancer
screening for 11-13
Heterogeneity
discrete heterogeneity 6-1
Histocompatibility testing
in organ transplantation 9-8
in red cell transfusion 9-10
HLA antigens
definition 9-8
typing 9-9
Homeostatic systems
endocrine systems
see
endocrine systems
dysfunction 7-7
regulatory function 7-6
Hormones
bioactive fraction 7-14
plasma protein binding 7-12
use in evaluation of endocrine function 7-8
I J
Immune complex-mediated injury
markers 9-5
pathobiology 9-5
Immunologic injury
autoimmune disease 9-5
immune complex deposition 9-5
mechanisms of injury 9-5
tissue transplantation 9-8
Imprecision
see
variability, method imprecision
Incorporation bias
in evaluation of classification studies 4-2
Infection
acute phase response 9-13
antimicrobial susceptibility testing 9-17
demonstration of infectious agent
direct microscopy 9-14
culture 9-14
immune response 9-16
microbial substances 9-15
specimen collection 9-14
hepatitis, viral 9-16
neutrophilia 9-13
Infectious agents
antimicrobial susceptibility testing 9-17
direct microscopy 9-14
culture 9-14
microbial substances 9-15
specimen collection 9-14
Injury
diagnostic window 9-3
estimating magnitude 9-4
immunologic injury 9-5
infection 9-12
injury versus death 9-1
test panels 9-4
tissue specificity of injury markers 9-2
Interindividual variability
Index
5
